Language selection

Search

Patent 2272136 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 2272136
(54) English Title: PYRAZOLE DERIVATIVES HAVING CRF ANTAGONIST ACTIVITY
(54) French Title: DERIVES DE PYRASOLE AYANT UNE ACTIVITE ANTAGONISTE CRF
Status: Deemed expired
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07D 231/44 (2006.01)
  • A61K 31/41 (2006.01)
  • A61K 31/415 (2006.01)
  • A61K 31/435 (2006.01)
  • A61K 31/495 (2006.01)
  • A61K 31/505 (2006.01)
  • A61K 31/535 (2006.01)
  • C07D 231/14 (2006.01)
  • C07D 401/00 (2006.01)
  • C07D 403/00 (2006.01)
  • C07D 403/12 (2006.01)
  • C07D 405/00 (2006.01)
  • C07D 409/00 (2006.01)
  • C07D 409/12 (2006.01)
  • C07D 413/00 (2006.01)
  • C07D 417/00 (2006.01)
  • C07D 471/04 (2006.01)
  • C07D 487/04 (2006.01)
  • C07D 519/00 (2006.01)
(72) Inventors :
  • FARACI, WILLIAM S. (United States of America)
  • WELCH, WILLARD M., JR. (United States of America)
(73) Owners :
  • PFIZER LIMITED (United States of America)
(71) Applicants :
  • PFIZER LIMITED (United States of America)
(74) Agent: SMART & BIGGAR
(74) Associate agent:
(45) Issued: 2004-12-07
(22) Filed Date: 1993-11-03
(41) Open to Public Inspection: 1994-06-23
Examination requested: 1999-06-01
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
07/992,225 United States of America 1992-12-17

Abstracts

English Abstract





Disclosed are pyrazole derivatives of the formula:

(see formula I-b)

(wherein R1 is hydrogen or a substituent such as NH2; R2 is
hydrogen or a substituent such as SCH3; R3 is a cyclic group
such as an optionally substituted phenyl; and R4 is a cyclic
group such as a substituted phenyl) having corticotropin-
releasing factor (CRF) antagonist activity and useful for
treatment of diseases induced by CRF.


Claims

Note: Claims are shown in the official language in which they were submitted.



-54-

CLAIMS


1. A compound of the formula:

Image

wherein:
R1 is amino, NH (C1-C6 alkyl) or
N(C1-C6 alkyl)(C1-C6 alkyl);
R2 is C1-C6 alkyl, amino, O(C1-C6 alkyl),
NH(C1-C6 alkyl), N(C1-C6 alkyl) (C1-C6 alkyl), SH or
S(O)n(C1-C6 alkyl) (in which n=0, 1 or 2);
R3 is phenyl or naphthyl, wherein the phenyl or
naphthyl may be substituted by one to three substituents
each independently selected from the group R5;
R4 is phenyl or naphthyl, wherein the phenyl or
naphthyl is substituted by one to three substituents each
independently selected from the group R5;
R5 is fluoro, chloro, bromo, trifluoromethyl,
C1-C6 alkyl or C1-C6 alkoxy, wherein the C1-C6 alkyl may be
substituted by hydroxy;
provided that when R1 is NH2 and R3 is
p-chlorophenyl, R4 is not 2,6-dichloro-4-trifluoromethyl
phenyl or 6-bromo-2-chloro-4-trifluoromethyl phenyl;


-55-


or a pharmaceutically acceptable acid addition
salt thereof.

2. The compound or salt according to claim 1, wherein
R3 is phenyl substituted with one or two substituents
independently selected from the group consisting of fluoro,
chloro, bromo, trifluoromethyl, C1-C6 alkyl and C1-C6 alkoxy.

3. The compound or salt according to claim 1 or 2,
wherein R4 is 2,4,6-trichlorophenyl, 2,4,6-trimethylphenyl,
2,6-dichloro-4-trifluoromethylphenyl or
4-bromo-2,6-dimethyl-phenyl.

4. The compound or salt according to any one of
claims 1 to 3, wherein R1 is amino, methylamino or
dimethylamino.

5. The compound or salt according to any one of
claims 1 to 4, wherein R2 is methylthio or ethyl.

6. The compound or salt according to claim 1, wherein
the compound has the formula:

Image

wherein:
R11 is H, 2-i-propyl, 2-OCH3, 2-Cl or 3-CF3;


-56-


R1 is NH2 or N (CH3) 2;
R13 and R15 are chloro; and
R14 is chloro or trifluoromethyl.

7. A composition for the treatment of (a) illness
induced or facilitated by corticotropin releasing factor or
(b) stress-induced illness which comprises (1) an effective
amount of the compound or salt of any one of claims 1 to 6,
and (2) a pharmaceutically acceptable carrier.

8. A commercial package comprising the composition of
claim 7, and instructions for the therapeutic use thereof.

9. Use of the compound or salt of any one of
claims 1 to 6, for the treatment of (a) illness induced or
facilitated by corticotropin releasing factor or (b) stress-
induced illness.

10. Use of the compound or salt of any one of
claims 1 to 6 in the manufacture of a medicament for the
treatment of (a) illness induced or facilitated by
corticotropin releasing factor or (b) stress-induced
illness.

Description

Note: Descriptions are shown in the official language in which they were submitted.



CA 02272136 1999-06-O1
-1-
PYRAZOLE DERTVATTVES HAVING CRF ANTAGONTST ACTIVITY
This is a divisional application of Canadian Patent
Application Serial No. 2,150,483 filed November 3, 1993.
This invention relates to pyrazole derivatives having
corticotropin-releasing factor (CRF) antagonist activity and
pharmaceutical compositions containing them.
The subject matter of this divisional application is
restricted to the compounds of the formula I-b described here-
inunder. However, it should be understood that the expression
"this invention" or the like encompasses the subject matter of
both the parent and this divisional applications.
CRF antagonists are mentioned in U. S. Patents Nos.
4,605,642 and 5,063,245 referring to peptides and pyrazolinones,
respectively. The importance of CRF antagonists is set out in
the literature, e. g. as discussed in U. S. Patent No.
5,063,245. A recent outline of the different activities
possessed by CRF antagonists is found in M. J. Owens et al.,
Pharm. Rev., Vol. 43, pages 425 to 473 (1991). Based on the
research described in these two and other references, CRF
antagonists are effective in the treatment of a wide range of
diseases including stress-related illnesses, such as stress-
induced depression, anxiety, and headache, abdominal bowel
syndrome, inflammatory diseases; immune suppression; human
immunodeficiency virus (HIV) infections; Alzheimer's disease;
gastrointestinal diseases; anorexia nervosa; hemorrhagic
stress; drug and alcohol withdrawal symptoms; drug addiction;
and fertility problems.
The compound of formula I below wherein A is C=O,
R1 is amino, R2 is methylthio, R3 is 2-chlorophenyl, and R4 is
2,4,6-trichlorophenyl is a commercial compound of no known
utility.
The present invention relates to compounds of the
formula:
64680-810D


CA 02272136 1999-06-O1
-la-
R3
A R
2
z
N
N~
Rl I
R4
and the acid addition salts thereof, wherein A is C=O or S02,
or A and Rl together with the carbons to which they are
attached form pyrimidinyl or 5-pyridyl which may be substituted
by R5 which is hydrogen, Cl-C6 alkyl, fluoro, chloro, bromo,
hydroxy, amino, O(Cl-C6 alkyl), NH(C1-C6 alkyl), N(Cl-C6 alkyl)
(C1-C6 alkyl), SH, S(O)n(Cl-C6 alkyl) wherein n=0, 1 or 2,
wherein said C1-C6 alkyl may be substituted by from 1 to 3
substituents R6 which is hydroxy,
64680-810D


CA 02272136 1999-06-O1
-2-
amino, C,-C3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino,
NH(C=O)CH" fluoro, chloro, bromo or C,-C3 thioalkyl;
R, is hydrogen, C,-Ce alkyl, amino, O(C,-Ce alkyl), NH(C,-Cs alkyl), N(C,-Ca
alkyl)(C,-Ce alkyl), wherein said C,-Ce alkyl may be substituted by from 1 to
3
substituents Re as defined above;
Rz is hydrogen, C,-CQ alkyl, hydroxy, amino, O(C,-Ce alkyl), NH(C,-CQ alkyl),
N(C,-Ce alkyl)(C,-CQ alkyl), SH, S(O)"(C,-Ce alkyl) wherein n = 0, 1, or 2,
cyano,
hydroxy, carboxy, or amido, wherein said alkyls may be substituted by one to
three of
hydroxy, amino, carboxy, amido, NH(C=O)(C,-Ce alkyl), N(C,-CQ alkyl)(C,-Ca
alkyl),
(C=O)O(C,-Ce alkyl), C,-C, alkoxy, C,-C, thioalkyl, fluoro, bromo, chloro,
iodo, cyano
or vitro;
R, is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinoiyl,
pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazoiyl, isothiazolyl,
benzoisothiazolyi, thiazolyi, isoxazolyl, benzisoxazolyl, benzimidazolyl,
triazolyl,
pyrazolyl, pyn-olyl, indofyi, azaindolyl, benzoxazolyl, oxazolyl, pyn-
olidinyl, thiazolidinyl,
morpholinyi, pyridinyl, tetrazolyl, or 9 to 12 membered bicycloalkyl,
optionally containing
one to three of O, S or N-Z wherein Z is hydrogen, C~ C4 alkyl, C,-C4
alkanoyi, phenyl
or phenylmethyl, wherein each one of the above groups may be substituted
independently by from one to three of fluoro, chforo, bromo, C,-CQ alkyl, C,-
CQ alkoxy,
or trifluoromethyl, or one of cyano, vitro, amino, NH(C,-CQ alkyl), N(C,-C4
alkyl)(C,-Cz
alkyl), COO(C,-C4 alkyl), CO(C,-C4 alkyl), SO=NH(C,-C~ alkyl), SO~N(C,-C4
alkyl)(C,-Cz
alkyl), SO=NHZ, NHSO=(C,-C4 alkyl), S(C,-Ca alkyl), SO=(C,-Ce alkyl), wherein
said C,-C4
alkyl and C,-Ce alkyl may be substituted by one or two of fluoro, chloro,
hydroxy,
amino, methyiamino, dimethylamino or acetyl; and
R4 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyi, pyrazinolyl,
pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl,
benzois~othiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl,
triazolyl,
pyrazolyl, pyn-olyi, indolyt, azaindolyl, benzoxazolyl, oxazolyl,
pyrrolidinyl, thiazolidinyl,
morphoiinyl, pyridi~yi, tetrazolyi, or 3 to &membered cycloalkyf or 9 to 12-
membered
bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is
hydrogen,
C,-C4 alkyl, C,-C~ alkanoyl, phenyl or phenylmethyl, wherein each of the above
groups
may be substituted independently by from one to three of fluoro, chloro,
bromo,
triftuoromethyl, C,-Ce alkyl or C,-CQ alkoxy, or one of cyano, vitro, amino,
NH(C,-CB


CA 02272136 1999-06-O1
alkyl), N(C,-C~ alkyl)(C,-CZ alkyl), COO(C,-C4 alkyl), CO(C,-C4 alkyl),
SOzNH(C,-C4
' alkyl), S02N(C,-C4 alkyl)(C,-Cz alkyl), SOZNH=, NH=SOz(C,-C4 alkyl), S(C,-CQ
alkyl),
SOz(C,-Ce alkyl), wherein said C,-C4 alkyl and C,-Ce alkyl may be substituted
by one
or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or
acetyl;
provided that (1 ) R4 is not unsubstituted phenyl; (2) when R, is amino, RZ is
methytthio,
R, is 2,4,6-trichlorophenyi, and A is C=O, then R3 is not 2-chlorophenyi; and
(3) R, and
R= are not both hydrogen.
More specific compounds of the formula I include those wherein R3 is phenyl
substituted independently with one or two of fluoro, chloro, bromo, methyl,
trifluoromethyl, vitro, C,-CQ alkyl, C,-Ce alkyioxy, SOZNHZ, SOzNH(C,-CQ
alkyl), SOZN(C,
CQ alkyl)?, or R3 is primary, secondary or tertiary alkyl of from 4-9 carbon
atoms wherein
said C4 Ce alkyl may contain from one to two double or triple bonds and may be
substituted by from 1 to 3 substituents RQ which is hydroxy, amino, C,-C3
alkoxy,
dimethylamino, diethylamino, methylamino, ethylamino, NH(C=O)CH3, fluoro,
chioro,
bromo, or C,-C, thioalkyl.
More specific compounds of the formula I are those wherein A is C=O, those
wherein R, is amino, methyiamino or dimethylaminQ; those wherein RZ is ethyl
or
methytthio and those wherein R4 is 2,4,6-trichlorophenyl, 2,4,6-
trimethylphenyl, 2,6-
dichloro-4.-trifluoromethylphenyl or 4-bromo-2,6-dimethyiphenyl.
More specific compounds of formuta I further include those wherein R3 is
phenyl
which may be substituted at positions 2 or 5 with one or two of methyl, C2-Ce
straight-
chain or branched alkyl, trifluoromethyl, fluoro, chloro, bromo or vitro,
those wherein
A and R, together form a pyrimidine ring, such that the bicyclic structure
formed is
pyn3zolo[3,4-d)pyrimidine, and RS is substituted at the 6 position; and those
wherein R3
is phenyl substituted independently with one or two of fluoro, chloro, bromo,
methyl,
trifluoromethyl, vitro, C,-Ce alkyl, C,-Ce alkyioxy, S02NH2, SO=NH(C,-Ce
alkyl), or
S02N(C,-Cealkyl)=, R4 is 2,4,6-trichforophenyl, 2,4,6-trimethytphenyl, 2,6-
dichioro~-
trifluoromeifiylphenyl or 4-bromo-2,6-dimethylphenyl, and RT is methytthio,
methyl or
ethyl.
. More speafic compounds of formula I also include those wherein R3 is phenyl
substituted independently with one or two of fluoro, chloro, bromo, methyl,
trifluoromethyi, vitro, C,-Ce alkyl, C,-CQ alkyloxy, S02NHZ, SOZNH(C,-Ce
alkyl),
SOZN(C,-CQ alkyl)Z, or R3 is primary, secondary or tertiary alkyl of from 4-9
carbon

CA 02272136 2003-02-19
69331-28D
-4-
atoms wherein the C4-C9 alkyl may contain from one to two
double or triple bonds and may be substituted by from 1 to 3
substituents R6 which is hydroxyl, amino C1-C3 alkoxy,
dimethylamino, diethylamino, methylamino, ethylamino,
NH (C=O) CH3, fluoro, chloro, bromo or C1-C3 alkylthio; R4 is
2,4,6-trichlorophenyl, 2,4,6-trimethylphenyl, 2,6-dichloro-
4-trifluoromethylphenyl or 4-bromo-2,6-dimethylphenyl; R1 is
amino, methylamino or dimethylamino; and R2 is methylthio or
ethyl.
Claimed in this divisional application are
compounds of the formula:
R3
SOz RZ
I-b
R ~ Ni
R4
wherein R1, R2, R3 and R4 are as defined for the formula I,
namely, the compounds of the above formula I in which A is
S02, provided that (1) R4 is not unsubstituted phenyl; (2) R1
and R2 are not both hydrogen; (3) R2 is not -OH, -O-CH2-CH2-
CH2-OH, -O-CH2-CH2-CH2-halogen or
-O-CH2-CH2-CH2- (dialkylamino) ; and (4) when Rl is NH2 and R3
is p-cholorophenyl, R4 is not 2,6-dichloro-4-trifluoromethyl
phenyl or 6-bromo-2-chloro-4-trifluoromethyl phenyl); and
pharmaceutically acceptable salts thereof.
The most preferred compounds of the invention are
[5-amino-1-.(2,6-dichloro-4-trifluoromethylphenyl)-3-methyl-
sulfanyl-1H-pyrazol-4-yl]-(2,5-dimethylphenyl)methanone,
[5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methyl-


CA 02272136 2003-02-19
69331-28D
-4a-
sulfanyl-1H-pyrazol-4-yl]-(2,5-bis-trifluoromethylphenyl)-
methanone, [5-amino-1-(2,6-dichloro-4-
trifluoromethylphenyl)-3-methyl-sulfanyl-1H-pyrazol-4-yl]-
(5-isopropyl-2-methylphenyl)methanone,[5-amino-3-
methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-
(5-isopropyl-2-methylphenyl)methanone, and [5-amino-1-(4-
bromo-2,6-dimethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-
(2,5-dibromophenyl)methanone.


CA 02272136 2004-04-20
64680-810D
4b
The invention also relates to a composition for the
treatment of illnesses induced or facilitated by corticotropin
releasing factor which comprises a compound of the formula I
as defined above or the known compound of formula I wherein A
is C=O, R1 is amino, R2 is methylthio, R3 is 2-chlorophenyl,
and R4 is 2.;4,6-trichlorophenyl, in an amount effective in
the treatment of said illnesses, and a pharmaceutically accept-
able carrier, and to a composition for the treatment of
inflammatory disorders, stress and anxiety related disorders
including stress-induced depression and headache, abdominal
bowel syndrome, immune suppression, HIV infections, Alzheimer's
disease, gastrointestinal diseases, anorexia nervosa,
hemorrhagic stress, drug and alcohol withdrawal symptoms, drug
addiction, and fertility problems, which comprises a compound
of the formula I as well as the known compound, both as defined
above in an amount effective in the treatment of said disorders,
and a pharmaceutically acceptable carrier. More specific and
most preferred compositions for the treatment of such illnesses
and disorders comprise a more specific and most preferred
compound of formula I as defined above.
Compositions of the invention may be contained in
a commercial package, together with instructions for the
therapeutic use thereof.


CA 02272136 1999-06-O1
The invention further includes a method for the treatment of illnesses induced
or facilitated by corticotropin releasing factor by administering to a subject
in need of
such treatment a compound of formula I or the known compound, Goth as defined
above, and a method for the treatment of stress and anxiety related disorders,
including
stress-induced depression and headache, abdominal bowel syndrome, inflammatory
disorders, immune suppression, HIV infections, Alzheimer's disease,
gastrointestinal
diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal
symptoms, drug addiction, and fertility problems, particularly depression, by
administering to a subject in need of such treatment a compound of formula I
as well
1 ~ as the known compound, both as defined above. More specific and most
preferred
methods forthe treatment of such illnesses and disorders comprise a more
specific and
most preferred compound of formula I as described above.
Whenever reference is made herein to C,-Ce alkyl, a straight or branched chain
alkyl of one to six carbon atoms is meant, such as methyl, ethyl, isopropyl or
hexyt.
Whenever reference is made herein to C,-Ce alkyl, in the definition of R5 and
R,,
this includes unsaturated CZ Ce alkyl, such as C2-Ce alkyl having one double
or triple
bond, C; Ce alkyl having two double bonds, and C4 Ce alkyl having two triple
bonds.
Whenever reference is made hereafter to a compound of formula I, this includes
the known compound of formula I as described above.
2~ Whenever R~ is a heterocyctic group, the attachment to A, defined above, is
through one of the carbons in the heterocydic group. Similarly, when R4 is a
heterocydic group, the attachment to the nitrogen in the pyrazole ring is
through one
of the carbons in the heterocydic group.
Whenever reference is made herein to 3- to &membered cydoalkyl or 9- to 12
membered bicydoalkyt containing one to three of O, S or N-Z, it is understood
that the
oxygen and sulfur ring atoms are not adjacent to each other.
The compounds of the formula t wherein R, is amino or C,-Ce alkyl, and Rz is
methylthio, having the formula II .(not shown), may be prepared from a
compound of
the formula


CA 02272136 1999-06-O1
- R3-' A -C -Rio
III
(SCH3)2
wherein R,o is cyano or C(O)(C,-Ce alkyl) and A and R, are as defined above
with
reference to formula I, by reaction with a compound of the formula
R4-NHNH2 I V
wherein R4 is as defined with reference to formula I. This reaction is
generally carried
out in a polar solvent, such as a C,-Ce alcohol. The reaction temperature
generally
ranges from about 20°C to about 160°C, and is conveniently the
reflux temperature of
the reaction mixture.
The compounds of formula III may be prepared by treating a compound of the
formula
Ra_A-CH2Rio V
with a base such as sodium hydride, in the presence of carbon disulfide
followed by
reaction of the formed intermediate with methyl iodide in a reaction solvent
such as
dimethylsulfoxide.
The compounds of formula IV are readily available or may be obtained by
methods known in the art.
The compounds of formula V may be prepared by known methods.
The compounds of the formula I wherein Rz is alkoxy, amino, or mono- or
disubstituted amino may be prepared by using the above procedure with R4NHNH2
from the corresponding compounds of the formula
R3-A-C-Rio Ra-A-C'Rlo
OR C
. (OR)2 (NR~R~~)
2


CA 02272136 1999-06-O1
-7-
. wherein A and R, are as defined with reference to formula I, R,° is
as defined with
-reference to formula III, and R, R' and R" are each hydrogen or C,-CQ alkyl
in
accordance with the definifion of RZ above.
The compounds of the formula 1 wherein R, is C,-Ce alkoxy or C,-CQ alkylthio
and Rz is C,-Ce alkyl may be prepared from a compound of the formula
R3
A R2
II ix
R x N/N
i
R4
wherein RX is chloro or bromo, Rz is C,-Ce alkyl, and R3, R4 and A are as
defined above
with reference to formula I, with a C,-Cs alcohol or C,-Ce mercaptan in the
presence of
a base. The reaction is generally carried out in a polar solvent such as
ethanol or t-
butanol at temperatures from about 20°C to about 160°C and
conveniently room
temperature.
The compounds of the formula IX may be prepared by treating a compound of
the formula
2o R
~3
A R2
IN X
H 0 ~N/
4
with a halogenating agent such as thionyl chloride or bromide, or phosphorous
oxychloride or pentachloride, or phosphorous oxybromide or pentabromide. The
reaction may be carried out without a solvent or in an aprotic solvent such as
methylene chloride, or dichloroethane at temperatures of about 0 ° C to
about 100 ° C.
Compounds of formula X may be prepared by treating compounds of the
formula


CA 02272136 1999-06-O1
R2
II XI
/N
N
Ra
with an activated derivative of a carboxylic or sulfonic acid of the formula
R3AOH, such
as an acid chloride of the formula R3ACI wherein R3 and A are as defined with
reference
to formula I, in the presence of calcium hydroxide in an aprotic solvent such
as dioxane
as described in Jensen, Acta Chem. Scand., 13, 1668-1670 (1959) at
temperatures of
from about 20°C to about 100°C. Compounds of the formula XI are
known in the art.
The compounds of the formula I wherein R, is C,-Ce alkoxy or C,-Ce alkyfthio
and RZ is C,-Ce alkytthio may be prepared from a compound of the formula
R3
p Rz
XII
R Y \N/
Ra
wherein RY is chloro or bromo and R,, R, and A are as defined above with
reference
to formula I, with a C,-Ce alcohol or C,-Ce mercaptan in the presence of a
base. The
reaction is generally carried out in a polar organic solvent such as ethanol
or t-butanol
at temperatures from about 20°C to about 160°C, conveniernty
room temperature.
The compounds of the fomnula XII may be prepared from a compound of the
formula
R3
R R2
~ IN X I I I
H 0 ~N/
Ra


CA 02272136 1999-06-O1

by reaction with a halogenating agent such as thionyi chloride or bromide, or
phosphorous oxychloride or pentachloride, or phosphorous oxybromide or
pentabromide. The reaction may be carried out with a solvent or in ari aprotic
solvent
such as methylene chloride or dichloroethane at temperatures of about
0°C to about
100°C.
The compounds of the formula Xlll may be prepared by treating a compound
of the formula
R2
1o II XIV
/N
N
R4
with activated benzoic or sulfonic acid derivatives, conveniently an acid
chloride, in the
presence of calcium hydroxide in an aprotic solvent such as dioxane as
described in
the above reference by Jensen.
The compounds of the formula XIV may be prepared by treating a compound
of the formula
R
Z
II XV
/N
N
R4
wherein Rz is chloro, bromo with a C,-Ce mercaptan in the presence of a base.
The
reaction is generally carried out in a polar organic solvent such as t-butanol
at
temperatures from about 20°C to about 160°C, conveniently the
reflux temperatures
of the reaction mixture.
The compounds of the formula XV may be prepared from compounds of the
formula


CA 02272136 1999-06-O1
-10-
OH
II xV I
/N
N
R4
with a halogenating agent such a thionyi chloride or bromide, or phosphorous
oxychloride or pentachloride, or phosphorous oxybromide or pentabromide. The
reaction may be carried out without a solvent or in an aprotic solvent such as
methylene chloride or dichloroethane at temperatures of about 0°C to
about 100°C.
The compounds of the formula I wherein R, is C,-Ce alkoxy or C,-CQ alkylthio
and RZ is C,-Ce alkoxy may be prepared from a compound of the formula
R .~
2
XVII
R,
Ra
wherein R,~,~ is chloro or bromo, Rz is C,-Ce alkoxy and R,, R4 and A are as
defined
above with reference to formula I, with a C,-CQ alcohol or C,-Ce mercaptan in
the
presence of a base. The reaction is generally carried out in a polar organic
solvent
such as ethanol or t-butanol at temperatures from about 20°C to about
160°C,
conveniently the reflex temperature of the reaction mixture.
The compounds of the formula XVII may be prepared from a compound of the
formula
R .~
2
3o XVIII
H
i
Ra


CA 02272136 1999-06-O1
_11_
by reaction with a halogenating agent such as thionyl chloride or bromide, or
phosphorous oxychloride or pentachloride, or phosphorous oxybromide or
pentabromide. The reaction may be carried out without a solvent or in an
aprotic
solvent such as methylene chloride, or dichloroethane at temperatures of about
0°C
to about 100 ° C.
The compounds of the formula XVIII may be prepared by treating a compound
of the formula
R2
1o II XIX
/N
N
i
R4
with an activated derivative of a carboxylic or sutfonic acid of the formula
R3AOH,
conveniently an acid chloride of the formula R,ACI wherein R3 and A are as
defined
above with reference to formula I, in the presence of calcium hydroxide in an
aprotic
solvent such a dioxane as described by Jensen in the reference cited above.
The compounds of the formula XIX may be prepared by treating a compound
of the above formula XV with an alcohol in the presence of a base. The
reaction is
generally carried out in a polar organic solvent such as ethanol at
temperatures from
about 20°C to about 160°C, conveniently the reflex temperatures
of the reaction
mixture.
The compounds of the formula I wherein _ R, is amino and R= is O(C,-Csallryl)
may be prepared by reacting a compound of the formula
R
~3
0 ( C1-C6 a 1 k y 1 >
XX
wherein R,, R4 and A are as defined above with reference to formula I, with
hydrazine
in a solvent such as a C,-CQ alcohol, conveniently at the boiling point of the
solvent.


CA 02272136 1999-06-O1
-12-
The compounds of the formula XX may be prepared by treating a compound
of the formula
R3
R OH
Q ~ IN X X I
R
'Q 4
wherein R,, R4 and A are as defined above with reference to formula i, with an
alkylating
agent such as di(C,-Ce alkyl) sulfate, and a base such as sodium hydride, in a
solvent
such as dimethylsulfoxide.
The compounds of the formula XXI may be prepared by treating a compound
of the formula
OH
0
XXII
I
Ra
'Q
with an activated derivative of a carboxylic or suffonic acid of the formula
R3AOH such
as an acid chloride of the formula R,ACI, wherein R3 and A are as defined with
reference to formula I, in the presence of a Lewis acid such as aluminum
chloride in an
aprotic solvent such as methylene chloride, dichioroethane, or
tetrachloroethane, at
temperatures of about 0 ° C to about 150 ° C.
The compounds of the formula XXII may be prepared by treatment of a
compound of the formula


CA 02272136 1999-06-O1
-13-
OH
XXIII
H 2 N \N/
I
Ra
with phthalic anhydride in acetic acid at the boiling point of the solvent.
The compounds of the formula XXIII may be prepared by contacting cyanoacetyi
chloride with R4NHNHZ in the presence of a base followed by heating the
resulting
hydrazide at reflux in alcoholic solution in the presence of a base.
The compounds of formula I wherein A and R, are taken together to form
pyrimidinyl have the formula
R .~
Rz
XXIV
R,
J
Ra
wherein Rz, R3, R4, and RS are as defined above with reference to formula I.
These
compounds may be prepared by cyclization of a compound of the above formula I
wherein A is C=O and R, is amino with a compound of the formula
0
I i
R5-C-NH2 XXV
wherein R5 is as defined with reference to formula I. This reaction is
generally carried
out at 100 to 250°C, and conveniently at the reflex temperature of the
compound XXV.
The compounds of formula I wherein A and R, are taken together to form 5-
pyridyi have the fomnula

CA 02272136 1999-06-O1
-14-
- R3
R2
XXVI
R5
Ra
wherein RZ, R3, R4 and R5 are as defined with reference to formula I. These
compounds
may be prepared as shown in Reaction Scheme 1.
Reaction Scheme 1
0
0 0
R3-C-CH3 + CzH50C-CH2-CH-N
R
5
XXVII XXVIII
0
R3-C-CHz-C-CHz-CHRS-N/
0 0
0
XXIX


CA 02272136 1999-06-O1
-15-
13 ~ IS
O~~C~CHz CH\N
0
H3C0 R2
XXX
Ra Re R3
Re
H I ~N
0 Rs'~- CH2 N
N ~ Rs N/ XXVI
0 Rs
Ra
XXXI XXXII
The compounds of formula XXIX are prepared by reacting a ketone of the
formula XXVII with a compound of the formula XXVIII in a suitable solvent such
as
tetrahydrofurane in the presence of a base such as sodium hydride. The
reaction is
conveniently carried out at the reflux temperature of the reaction mixture.
The compound XXIX is reacted with a compound of the formula R2C(OCH3)3 to
form the compound XXX. The reaction is carried out in a suitable solvent such
as ethyl
acetate, conveniently at the reflux temperature of the reaction mixture. The
wavy line
-- in formula XXX indicates that either isomer of this compound is included,
in
accordance with accepted convention for indicating stereoisomers.
The compound XXXI is prepared by reacting compound XXX with a hydrazine
of the formula H=NNHR4 wherein R, is as defined with reference to formula I.
The
reaction is carried out in a suitable solvent such as ethanol, conveniently at
the reflux
temperature of the reaction mixture.
The compounds of formula XXVI wherein R5 is linked to position 6 is formed by
first ~ reacting compound XXXI with hydrazine hydrate in a suitable solvent
such as
ethanol, conveniently at the reflux temperature of the reaction mixture. The
compound
XXXII is separated from precipitated phthalhydrazide and taken up in an
organic solvent


CA 02272136 1999-06-O1
-16-
such as toluene. The compound XXVI is formed by dehydrogenation of compound
~OCII with palladium over carbon.
Reaction Scheme 1 shows the preparation of compounds XXVl~vherein RS is in
the 6-position. A similar reaction sequence may be followed to prepare
compounds
XXVI wherein Rs is in the 7-position by replacing compound XXVIII by a
compound of
the formula
0 _
0
1p C2H50C-CH-CH2-N XXX I I I
0
The compounds of formula I wherein A is C=O and R, and RZ are the same
group R, may be prepared by reacting a B-ketone of the formula
0
II II
R7 C~CH2~C~R7
with the hydrazine of the formula IV as defined above to form a pyrazole
compound of
the formula
R7
\N
R 7 N~
Ra
The reaction proceeds at reflux in an appropriate solvent such as ethanol.
After
brominafion of the pyrazole compound, e.g. with bromine in acetic acid, to
form the
corresponding 4-bromo derivative and conventional metallation, e.g, with t-
butyl lithium,
at -78 ° C in tetrahydrofuran, a suitably activated R3 carboxylic acid
such as the acid
chloride R,C(O)CI is added to give the desired compound I.


CA 02272136 1999-06-O1
-17-
The compounds of formula I wherein A is C=O and R, and R2 are not the same,
and wherein R, or R2 is attached through a CZH4 fragment, may be prepared from
a
pyranone of the formula
0 0
~a
3
,,~, xxxrv
Rii ~2
wherein R3 is as defined above, and R= is as defined above when R" is C; CQ
alkyl
which may be substituted by 1 to 3 of RQ, or R2 is R, when R" is C,-Ca alkyl
which may
be substituted by one to three of hydroxy, amino, carboxy, amido, NH(C=O)(C,-
Ce
alkyl), N(C,-Ce alkyl)(C,-Ca alkyl), (C=O)O(C,-CQ), C,-C, alkoxy, C,-C3
thioslkyl, fluoro,
bromo, chloro, iodo, cyano or vitro. The compound ~CXIV is reacted with a
hydrazine
of the formula H2NNHR4 wherein R4 is as defined above to form compounds of the
formulae
~3 ~3
~C CHzCH(OH>R11 ~C R2
and '
Rz N/ R11-CH- N/
Ra OH H2 Ra
which on dehydration and hydrogenation result in compounds of the formulae
3
0!C C2H4R11 0%C Rz
~ I~ and ~ I
R~ N~ RiiH4C2 N/
R4 Ra
The compounds of the formula I wherein A is C=O and RZ is O(C,-Ce alkyl) may
be prepared by reacting a hydrazine of the formula R4NHNHZ with a compound of
the
formula (A) in a suitable solvent


CA 02272136 1999-06-O1
-1 &
OH
C .C H 3
R1 ~ Ri N/N
CH3 R
4
(A> (B>
such as THF or methyiene chloride and cyclization of the resulting hydrazide
with heat
to give the intermediate (t3). This compound may be reacted with an activated
carboxyclic acid derivative such as the acid chloride R3(C=O)CI in the
presence of a
Lewis acid such as aluminum trichloride in a solvent such as ethylene
dichloride at
temperatures of from about -10°C to about 80°C. The formed
compound of formula
I wherein R2 is hydroxy may be reacted with (C,-CQ alkyl)L wherein L is a
leaving group
such as chloro, bromo, or tosylate and C,-Ca alkyl may be substituted in
accordance
with the substituents in the definition of R2.
Those compounds of formula I wherein R, is ~C,-CQ alkylamino or di(C,-Ce
alkyl)amino may be prepared from corresponding compounds of formula I wherein
R,
is amino. When R, is methytamino or dimethyiamino, reaction is with a
methylating
agent such as methyl iodide. When R, is CZ-Ca alkyiamino or di(C2-Ce
aJkyl)amino,
reaction is with an alkyiating agent such as CZ-CQ alkyl-L wherein L is a
leaving group
such as chloro, bromo, tosylate, or mesylate. Both the methylation and the Cz-
Cs
alkylation is in the presence of a base such as sodium hydride and a solvent
such as
tetrahydrofuran, dimethyl formamide or dimethyl sutfoxide.
The acid addition sans are prepared in a conventional manner by treating a
solution or suspension of the free base of formula I with one chemical
equivalent of a
pharmaceutically acceptable acid. Conventional concentration or
crystallization
techniques are employed in isolating the salts. Illustrative of suitable acids
are acetic,
lactic, succinic, malefic, tartaric, citric, gluconic, ascorbic, benzoic,
cinnamic, fumaric,
sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sutfamic,
sutfonic acids
such as methanesutfonic, benzene sutfonic, p-toluenesulfonic, and related
acids.


CA 02272136 1999-06-O1
-19-
The compound of the invention may be administered alone or in combination
with pharmaceutically acceptable carriers, in either single or multiple doses.
Suitable
pharmaceutical carriers include inert solid diluents orflllers, sterile
aqueous solution and
various organic solvents. The pharmaceutics! compositions formed by combining
the
novel compounds of formula I and the pharmaceutically acceptable carriers are
then
readily administered in a variety of dosage forms such as tablets, powders,
lozenges,
syrups, injectable solutions and the like. These pharmaceutical compositions
can, if
desired, contain additional ingredients such as flavorings, binders,
excipients and the
like. Thus, for purposes of oral administration, tablets containing various
excipients
such as sodium citrate, calcium carbonate and calcium phosphate may be
employed
along with various disintegn3nts such as starch, alginic acid and certain
complex
silicates, together with binding agents such as poiyvinyipyn-olidone, sucrose,
gelatin
and acacia. Additionally, lubricating agents such as magnesium stesrate,
sodium Isuryl
sulfate and talc are often useful for tabletting purposes. Solid compositions
of a similar
type may also be employed as fillers in soft and hard filled gelatin capsules.
Preferred
materials for this include lactose or milk sugar and high molecular weight
polyethylene
glycols. When aqueous suspensions or elixirs are desired for oral
administration, the
essential acctive ingredient therein may be combined with various sweetening
or
flavoring agents, coloring matter or dyes and, if desired, emulsifying or
suspending
agents, together with diluents such as water, ethanol, propylene glycol,
glycerin and
combinations thereof.
For parenteral administration, solutions of the novel compound of formula I in
sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution
may be
employed. Such aqueous solutions should be suitably buffered if necessary and
the
liquid diluent first rendered isotonic with sufficient saline or glucose.
These particular
aqueous solutions are especially suitable for intravenous, intramuscular,
subcutaneous
and intraperitoneal administration. The sterile aqueous media employed are all
readily
available by standard techniques known to those skilled in the art.
Additionally, it is possible to administer the compounds of the present
invention
topically when treating inflammatory conditions of the skin and this may be
done by
way of creams, jellies, gels, pastes and ointments, in accordance with
standard
pharmaceutical practice.


CA 02272136 1999-06-O1
The effective dosage for the compound of formula I
depends on the intended route of administration and other
~ factors such as age and weight of the patient, as generally
known to a physician. The dosage also depends on the illness
to be treated, although in general the daily dosage will range
from about 0.1 to 50 mg/kg of the body weight of the patient.
More specifically, the daily dosage for stress-induced
illnesses will generally range from about 0.1 to 50 mg/kg of
the body weight of the patient to be treated, for treatment of
inflammatory diseases aboutØ1 to about 100 mg/kg will be
needed, for Alzheimer's disease, about 0.1 to about 50 mg/kg,
as well as for gastrointestinal diseases, anorexia nervosa,
hemorrhagic stress, and drug and alcohol withdrawal symptoms.
The pharmaceutical composition may be put in a
commercial package for practical use. Such commercial package
normally comprises a container in which the composition is
contained. The commercial package usually also comprises a
written matter which says that the pharmaceutical composition
can or should be used for the treatment described in this
specification.
The methods for testing the compounds for formula I
for their CRF antagonist activity are according to the
procedures of Endocrinology, 116, 1653-1659(1985) and
Peptides, 10,179-188(1985) which determine the binding
activity of a test compound to a CRF receptor. The binding
activity for the compounds of formula I generally ranges from
about 0.2 nanomolar to about 10 micromolar.
64680-810

CA 02272136 1999-06-O1
The following abbreviations are used in the Examples
Ph=phenyl; iPr-isopropyl; HRMS=high resolution mass spectrum.
Example 1
A. 2-Bromo-2',5'-dimethvlacetonhenone
A mixture of 10.60 g (0.10 mol) of para-xylene and
16.53 g (0.105 mol) of a-bromoacetyl chloride in 300 mL of
1,2-dichloroethane was cooled in an ice bath under an
atmosphere of dry N2 and treated portion wise with 14.15 g
(0.106 mol) of aluminum chloride. The reaction mixture was
stirred for 30 minutes at 0-5°C and then for 2.5 hours at room
temperature. The mixture was then poured onto ice and the
aqueous layer was acidified with concentrated HC1. The
organic layer was separated and the aqueous layer was
extracted twice with methylene dichloride. The combined
organic extracts were dried with brine solution and with
magnesium sulfate. The solvent was evaporated to give 23.87 g
of an amber oil which was for use in the next reaction without
further purification.
B. 2-Cvano-2',5'-dimethvlacetophenone
The product of the above reaction (approximately 0.10
mol) was dissolved in 300 mL of ethanol and was treated with a
solution of 16.25 g (0.25 mol) of potassium cyanide in 30 mL
of water and the resulting mixture was refluxed for 90
minutes. After
-20a-
64680-810


CA 02272136 1999-06-O1
-21-
cooling, the ethanol was stripped from the mixture on the rotary evaporator
and the
residues were made slightly acidic with concentrated hydrogen chloride. The
product
was extracted into ethyl acetate using precautions to avoid escape of hydrogen
cyanide. The organic extracts were dried with brine and with magnesium sulfate
and
evaporated to a gummy semi-solid. This was trtturated repeatedly with hot
hexane
which, on cooling, deposited needles to give the desired product, 8.50 g (4996
for the
two reactions), m.p. 75 - 76°C.
C. 3.3-Bis-methytthio-2-(2.5-dimethvlbenzoyl)-acryionifite.
A solution of 4.96 g (28.6 mmol) of 2-cyano-2',5'-dimethylacetophenone in 120
mL of dry dimethyl suffoxide and 3.43 mL (57.3 mmol) of carbon disulfide in a
flame-
dried 3-neck round bottom flask under dry nitrogen was stirred at 15 - 18
° C while 1.41
g (58.7 mmol) of oil free sodium hydride was added in 5 portions. The
resulting deep
red solution was stirred for 1 hour at 18 ° C and then cooled to 15
° C whereupon 3.92
mL (8.95 g, 63.0 mmol) of methyl iodide was added dropwise. The temperature
rose
to about 22°C during the addition. After stirring for 2 hours at room
tempen3ture, the
reaction mixture was poured into cold water and the aqueous layer was
extracted three
times with ethyl acetate. The combined extracts were washed three times with
water
and then dried with brine and magnesium sulfate. Evaporation gave 8.96 g of
the title
compound as a heavy orange oil which crystallized in the refrigerator. The
analytical
sample crystallized from ethanol, m.p. 74.5 - 75.5°C.
D. 5-Amino-1-(2.6-dichloro-4 trrfluoromethylphenyl~4-(2.5-dimethylbenzoyl)~
methyithiop~razole.
A suspension of 7.94 g (28.6 mmol) of the product of step C and 7.01 g (28.6
mmol) of 2,6-dichioro-4-trifluoromethylphenylhydrazine in 100 mL of ethanol
was heated
at reflux for 2 hours, solution occurring as the reaction mixture was warmed.
Then the
ethanol was mostly removed on the rotary evaporator and the residues were
partitioned
between dilute aqueous hydrogen chloride solution and ethyl acetate. The
organic
phase was washed once with water and with brine, then dried with magnesium
sulfate
and treated with decolorizing carbon. The filtered solution was evaporated and
the
residues crystallized from 10:1 hexane/ethyl acetate to give 12.00 g (8896) of
the title
product in two crops, m.p. 130 - 132 ° C.


CA 02272136 1999-06-O1
-22-
Example 2
5-Methytamino-4-(2-chlorobenzoyl)-3-methylthio-l-(2.4.6-
trichloroahenyl)oyrazole
and 5-dimethviamino-4-(2-chlorobenzoyl)-3-methytthio-1-(2.4,6-ttichlor~phenyi)-

PvrazOle.
A mixture of 0.50 g (1.16 mmol) of 5-amino-4-(2-chlorobenzoyl}~-methyithio-1-
(2,4,6-trichlorophenyt)pyrazole in 5 mL of tetrahydrofuran was treated with 50
mg (1.16
mmol) of sodium hydride and stirred at room temperature for 30 minutes. Then
0.75
ml (1.71 g, 12.0 mmol) of methyl iodide was added dropwise and the reaction
mixture
was stirred for 60 minutes at room temperature. The reaction mixture was then
quenched with water and the products were extracted into ethyl acetate.
Concentration
of the dried solution and chromatography on silica gel with mixture of hexane
and ethyl
acetate gave the less polar dimethytamino title compound (300 mg, 5496) as a
white
foam. Anal. Calcd. for C,9H,5ON3SCI4: C, 48.02; H, 3.18; N, 8.88. Found: C,
47.84;
H, 3.09; N, 9.01.
The more polar monomethyl title compound was isolated from the column in like
manner as a white foam (34 mg, 696). Anal. Calcd. for C,BH,3ON3SCI4: C, 46.88;
H,
2.84; N, 9.11. Found: C, 46.54; H, 2.89; N, 9.07.
Example 3
5-Amino-4-(2-methoxybenzoyl~-3-methytthio-1-(2.4.6-trichloroahenyi)pYrazole.
To a solution of 2-methoxyphenylmagnesium bromide prepared from 18.7 g
(0.10 mol) of 2-bromoanisole and 2.43 g (0.10 mol} of magnesium turnings in
ether
under dry nitrogen was added 1.6 g (5.0 mmol) of 5-amino-4-cyano-3-methylthio-
1-
(2,4,6-trichlorophenyl)pyrazole and the resulting mixture was stir-ed and
refluxed for 16
hours. Upon cooling, the reaction was decomposed with 50 mL of saturated
ammonium chloride solution. The organic phase was extracted with aqueous
hydrogen
chloride and the acidic extract was treated with 10 mL of concentrated
hydrogen
chloride and heated at 80 - 90 ° C for 10 minutes after which the
mixture was cooled and
made alkaline. Extraction with methyiene dichloride and chromatography of the
extracts with mixtures of hexane and ethyl acetate gave 313 mg (1496) of the
title
compound, m.p. 200-202°C. Anal. Calcd. for C,BH"OzN,SCl3: C, 48.82; H,
3.18; N,
9.49. Found: C, 48.54; H, 3.32; N, 9.09.


CA 02272136 1999-06-O1
-23-
ExamAle 4
_ A. 5-Amino-3-methyl-1-12.4.6-trichlorophenyllayrazole.
To a solution of 0.51 g (22.0 mmol) of sodium in methanol was added 1.66 g
(20.0 mmol) of 5-methylisoxazole. The reaction mixture as refluxed for 8 hour;
and
then stirred overnight at room temperature. Then 4.23 g (20.0 mmol) of 2,4,6
trichlorophenyihydrazine was added and the reaction mixture was again refluxed
for 4
hours. A second portion of sodium in methanol was added and reflux was
continued
for 24 hours. The reaction mixture was taken up with ether and dilute hydrogen
chloride. The organic extracts were washed with dilute hydrogen chloride and
brine,
and then dried with magnesium sulfate and evaporated to give crystals, m.p.
132-
134°C. Analysis of this material, particularly two CN bands in the IR
spectrum at 2190
crri' and 2250 cm-', revealed it to be a mixture of the cis- and traps-isomers
of 1-
cyanoacetone-2,4,6-trichlorophenylhydrazone. This material was suspended in
methanol and treated with 10.0 mmol of sodium methoxide in 5 mL of methanol.
After
5 minutes at room temperature, water was added to crystallize the product
which was
fettered off and washed well with water. After sir drying, the product weighed
2.21 g
(4096) and melted at 134.0-135.5°C. Despite the similarity in meting
points, the latter
material was distinctly different from the former, having an R, of 0.67 vs.
0.78 for the
intermediate on silica gel TLC plates developed with 1:1 hexane ethyl acetate
and a
distinctly different 300 MHz proton NMR spectrum.
B. 5-(2-Chlorobenzamido)-4-(2-chlorobenzoyl)-3-methyl-1-(2 4 6
trichlorophenyl)pyrazole.
A suspension of 2.34 g (17.50 mmol) of aluminum trichloride in 20 mL of
1,1,2,2
tetrachloroethane was treated with 2.02 mL (2.78 g, 15.9 mmol) of 2-
chlorobenzoyl
chloride and the resulting solution was stirred for 20 minutes at room
temperature.
Then 2.00 g (7.23 mmol) of the product of Step A was added and the reaction
mixture
was refluxed for 16 hours. The cooled reaction mixture was poured over ice and
the
insolubles were filtered off and washed with ethyl acetate. The organic layer
was
separated and the aqueous was washed twice with ethyl acetate. The combined
organic layers were dried over magnesium sulfate and evaporated. The residues
were
chromatographed on silica gel, eluting with 4:1 hexane ethyl acetate to give
2.05 g
(5196) of the title product, an amorphous foam. Anal. Calcd. for
Cz4H,4O2N3C15: C,
52.06; H, 2.55; N, 7.59. Found: C, 52.11; H, 2.57; N, 7.27.


CA 02272136 1999-06-O1
-24-
C. 5-Amino-4-(2-chlorobenzoyf)-3-methyl-1-12,4.6-trichlorophenyl)pyrazole.
A solution of 1.94 g (3.50 mmol of the product of Step B in 20 mL of glacial
acetic acid was treated with 20 mL of 4896 hydrogen bromide and stiaed ~at
reflex for
8 hours. The cooled reaction mixture was treated with water to crystallize the
product
which was separated by flttration, washed with water and air dried to give the
title
product, 1.45 g (10096), m.p. softens about 210°C and melts at
222°C. Anal. Calcd.
for C"H" ON3CI4: 412.9656. Found: 412.9722.
Example 5
5-Methylamino~-f2-chlorobenzoyl)-3-methyl-1-(2.4.6-trichforophenyl)pyrazole
and
5-dimethvlamino-4-(2-chlorobenzovl)-3-methyl-1-(2.4.6-
trichlorophenyl)pyrazole.
A solution of 0.208 g (0.5 mmol) of the compound of Example 4C in 20 mL of
tetrahydrofuran (THF) was stirred in an ice/water bath while 5.0 mL of 1.0 M
sodium
hexamethyldisilazide in THF was added followed by 0.5 mL (1.14 g, 8 mmol) of
methyl
iodide. The reaction mixture was then stirred overnight at room temperature.
The
reaction mixture was poured into water and the products were extracted into
ethyl
acetate, dried and concentrated. The residues were chromatographed on silica
gel
using 5:1 hexane/ethyl acetate as eluent to give the less polar dimethylamino
title
compound, 52 mg (2396), m.p. 108-109°C (ether/pentane).
The more polar product likewise crystallized from ether/pentane to give 39 mg
(1896) of the monomethylamino title compound, m.p. 174-175°C.
Example 6
5-amino-1-(2.6-dichloro-4-trifluoromethylphenyl)-4-12.5-dimethyibenzoyl)~-(n-
propyl)pVrazOle.
A solution of 0.52 g (3.0 mmol) of 2,5-dimethylbenzoylacetonitrile, 0.45 g
(3.0
mmol) of trimethyiorthobutyrate and 0.632 g (0.58 mL, 6.2 mmol) of acetic
anhydride
in 5.0 mL of ethyl acetate was refluxed overnight and then cooled. The
solvents were
removed in vacuo and the residues were dissohred in 10 mL of ethanol. One-half
of this
solution, containing 1.5 mmol of 1-cyano-1-(2,5-dimethylbenzoyl)~-methoxy-1-
pentene
was mixed with 0.7 mL (0.51 g, 5.0 mmol) of triethylamine and 0.37 g (1.50
mmol) of
2,6-dichloro-4-trifluoromethylphenylhydrazine and refluxed for 2.5 hours. The
reaction
mixture was cooled and partitioned between dilute hydrogen chloride and ethyl
acetate.
The organic phase was washed with water and then dried with brine and with
magnesium sulfate. The solvent was evaporated to give an oil which was


CA 02272136 1999-06-O1
-25-
chromatographed on silica gel by the flash method eluting with 4:1
hexane/ethyi acetate
to give the title compound as an amorphous foam. Anal. Calcd. for
C~2H2°ON3CIzF"
469.0935. Found: 469.0889.
Example 7
A. 5-Amino-3-hydroxy-1-(2.4.6-trichlorophenyl)-cwrazote.
Cyanoacetic acid (8.5 g, 0.10 mol) in 200 mL of dry ether was treated with
20.8
g (0.10 mol) of phosphorous pentachloride, warmed briefly to reflux and let
cool to
room temperature at which time all of the phosphorous perrtachloride, had
dissolved.
After a small amount of insoluble material was removed by filtration, the
ether was
removed on the rotary evaporator. Then 100 mL of toluene was added and
stripped
to remove phosphorous oxytrichloride. The residual pale yellow oil was
immediately
dissolved in 50 mL of cold methylene dichloride and added to a cold suspension
of
21.15 g (0.10 mol) of 2,4,6-trichlorophenylhydrazine in 14.0 mL of
triethyiamine and 100
mL of methylene dichloride, keeping the temperature below 20°C by use
of an ice bath.
The reaction mixture was allowed to warn to room temperature and stirred for
one
hour. Then 500 mL of cold water was added. The precipitated solid was filtered
$nd
washed with water and with a little methylene dichloride to give the
intermediate 2-
cyano-N-(2,4,6-trichlorophenyl)acethydrazide, 14.92 g (5496), m.p. 166-
168°C. Anal.
Calcd. for C9HeON3: C, 38.81; H, 2.17; N, 15.09. Found: C, 38.83; H, 2.06; N,
14.81.
This material (14.92 g, 53 mmol) was dissolved in a solution of 2.80 g (0.12
mol)
of sodium in 200 mL of methanol and refluxed for 4 hours. After stirring
overnight at
room temperature, the methanol was mostly evaporated and the residues were
poured
into water. The aqueous layer was extracted with ether and was then acidified
with
concentrated hydrogen chloride. The product was extracted into ethyl acetate.
The
extracts were dried with brine and magnesium sulfate and evaporated to give a
foam
which crystallized from ether to give 12.28 g (9396) of the title product,
m.p. 221 -
223 ° C. Anal. Calcd. for CaHQON,: C, 38.81; H, 2.17; N, 15.09. .Found:
C, 38.81; H,
2.16; N, 14.84.
B. 3-Hvdroxv- 5-phthalimido-1-(2.4.6-trichlorophenyl)ayrazole.
A mixture of 4.50 g (18.0 mmol) of the compound of Step A and 2.81 g (19.0
mmol) of phthalic anhydride in 40 mL of glacial acetic acid was refluxed for 4
hours and
stir-ed overnight at room temperature. About two volumes of water were added
dropwise and the resulting solid was filtered and washed with water. The damp
solid


CA 02272136 1999-06-O1
-2tr
was taken up in a little ethanol, filtered and washed with a little ethanol
and ether, and
air dried to give the tifie compound, 5.11 g (6996), m.p. 295 -
298°C(dec). Anal. Calcd.
for C"HsO3N3C13: C, 49.97; H, 1.97; N, 10.28. Found: C, 49.28; H,-1.95; N,
10.06.
C. 4-(2-Chlorobenzoyl)-3-hydroxy-5-phthalimido-1-(2 4 6
trichloroohenyi)pyrazole.
Aluminum trichloride (2.34 g, 17.6 mmol) was added to a solution of 2-
chlorobenzoyl chloride in 60 mL of 1,1,2,2-tetrachloroethsne and the resulting
mixture
was stir-ed for 30 minutes at room temperature. Then 2.87 g of the compound of
Step
B was added all at once and the reaction mixture was refiuxed overnight. The
cooled
mixture was poured into water and the aqueous phase was extracted three times
with
ethyl acetate. The organic extracts were dried with brine and magnesium
sulfate and
evaporated to give a red oil which was taken up in methanol and crystallized
to give the
title compound, 2.97 g (7796), m.p. 245 - 246°C.
D. 4-l2-Chlorobenzoyl)-3-ethoxy-5-phthalimido-1 (2 4 6
trichlorophenyl)pyrazole.
A solution of 0.55 g (1.0 mmol) of the compound of Step C in 10 mL of dry
dimethyl sulfoxide was treated portionwise with 36 mg (1.5 mmol) of sodium
hydride
and the resulting mixture was stin-ed for 30 minutes at room temperature. Then
0.21
mL (0.25 g, 1.61 mmol) of diethyl sulfate was added and the reaction mixture
was
stirred for one hour at room temperature. The reaction mixture was poured into
water
and the product was extracted into ethyl acetate. The extracts were washed
with water
and dried with brine and magnesium sulfate, and evaporated to a gum. The
product
was crystallized from boiling ethanol to give the product (230 mg, 4096) as
fine crystals,
m.p. 215 - 216°C.
E. 5-Amino-l2-chlorobenzoyl)-3-ethoxy-1-(2 4 6-trichioroohenyl)ov~~azole.
A suspension of 184 mg of the compound of Step D in 10 mL of ethanol was
treated with 0.5 mL of 5596 hydrazine hydrate and refiuxed for 1 hour. Solids
in the
cooled reaction mixture were filtered off and discarded and the filtrate was
evaporated
to a gum which was triturated with ether and filtered. The filtrate was again
evaporated
to a foam which was shown to be 104 mg of the analytically pure title
compound. Anal.
Calcd. for C,8H,30ZN3CI4: C, 48.57; H, 2.94; N, 9.44. Found, C, 48.41; H,
2.52; N, 9.43.


CA 02272136 1999-06-O1
-27-
Example 8
' 5-Dimethylamino-4-l2-chlorobenzoyl)~-methoxy-1-(2.4.6-
trichloroahenyl)pyrazole.
A solution of 60 mg (0.14 mmol) of 5-amino-(2-chlorobenzoyl)~-methoxy-1
(2,4,6-trichlorophenyl) pyrazole prepared according to Example 7 in 5 mL of
dry
dimethyl sutfoxide was treated with 22 mg (0.88 mmol) of oil-free sodium
hydride to
give a yellow solution. After 1 hour at room temperature, 0.2 mL (0.46 g, 3.21
mmol)
of methyl iodide was added. After stirring for 5 hours, the reaction mixture
was poured
into water and the product was extracted into ethyl acetate. After drying with
brine and
magnesium sulfate, the solvent was removed to give the title product as a one-
spot
foam. 'H-NMR (CDCI,): 2.77 (6H, s), 3.63 (3H, s), 7.24 - 7.42 (4H, m), 7.48
(2H, s).
Example 9
A. 3.3-Bis-ethoxy-2-(3-trifluoromethylbenzoyl)-acrylonitrile.
Sodium (0.126 g, 5.5 mmol) was dissolved in 15 mL of ethanol and 20 mL of
dioxane was added followed by 1.59 g (5.0 mmol) of 3,3-bis-methytthio-2-(3
trifiuoromethylbenzoyl)-acrylonitrile and the reaction mixture was refluxed
for 4 hours
and let stir overnight at room temperature. This compound was relatively
unstable to
aqueous conditions and was not isolated as such. Instead, an aliquot of the
mixture
was stripped and the product was identified by 300 MHz proton NMR: NMR (DMSO-
dQ): 1.14 (6H, tJ = 7), 3.45 (4H, q, J = 7), 7.44 - 8.16 (4H, m).
B. 5-Amino-1-(2.6-dichloro-4-trifluoromethylphenyl)-3-ethoxy-4-(3-
trifluoromethylbenzoyl)pyrazole.
An aliquot of the above solution of step A containing approximately two
millimoles of 3,3-bis-ethoxy-2-(3-trifluoromethylbenzoyl)acrylonitrile was
reacted with
0.49 g (2.0 mmol) of 2,6-dichloro-4-trifluoromethylphenylhydrazine in 10 mL of
ethanol
under reflux overnight. The cooled mixture was poured into dilute hydrogen
chloride
(HCI) and the product was extracted into ethyl acetate (EtOAc), washed with
water and
brine, and dried over magnesium sulfate (MgS04). Chromatography on silica gel
with
4:1 hexane/EtOAc gave the title product, 320 mg (3196), m.p. T7 - 78°C
from pentane.
Example 10
_ 5-Amino-1-(2.6-dichloro-4-trifluoromethylphenyl)-4-(2.5-dimethylbenzoyl)-3-
ethoxypyrazole.
A solution of 0.26 g (1.5 mmol) of 2,5-dimethylbenzoylacetonitrile, 0.34 mL
(0.31
g, 1.60 mmol) of tetraethylorthocarbonate and 0.30 mL (0.33 g, 3.20 mmol) of
acetic


CA 02272136 1999-06-O1
-28-
anhydride in 10 mL of EtOAc was refluxed overnight. The solvent was evaporated
and
mL of absolute ethanol was added and then stripped. The residues were
dissolved
in 10 mL of ethanol, 368 mg (1.5 mmol) of 2,6-dichloro-4-trifluoromethylphenyl-

hydrazine and 0.7 mL (0.51 g, 5.0 mmol) of triethylamine were added, and the
mixture
5 was refluxed for 90 minutes. The mixture was poured into water, extracted
with EtOAc
and the organic extracts were washed with dilute HCI and brine, and dried over
MgSO,.
Evaporation gave a gum which was chromatographed on silica gel with 4:1
hexane/EtOAc to give the title product which crystallized from pentane, 15 mg
(2%),
m.p. 99 - 101 °C.
10 Example 11
1-(2.6-Dichloro-4-trifluoromethylphenyl)-5-methyl-4-j3-methylbenzoyl)-3-
methvtthioayrazole.
A solution of 2.97 g (16.9 mmol) of 4-(3-methylphenyl)butane-2,4-dione and
4.04
mL (5.14 g, 67.6 mmol) of carbon disulfide in 60 mL of dry dimethyl sutfoxide
was
treated portionwise with 0.89 g (37.1 mmol) of oil-free sodium hydride at 15 -
18 ° C.
After stirring 30 minutes, 2.31 mL (5.27 g, 37.1 mmol) of methyl iodide was
added
dropwise and the reaction mixture was allowed to stir at room temperature for
1 hour.
It was then poured into water and the product was extracted into ether,
baclcwashed
with water and dried over MgS04 to give 4.30 g (9196) of an oil which
crystallized in the
refrigerator overnight, m.p. 44 - 46 ° C. ' H-NMR (CDCI3): 2.16 (3H,
s), 2.38 (6H, s), 2.72
(3H, s), 7.26 - 7.38 (2H, m), 7.58 - 7.74 (2H, m). A mixture of 1.95 g (6.96
mmol) of 3,3-
bismethytthio-2-(3-methylbenzoyl}-2-acetylethene and 1.71 g of 2,6-dichloro-4-
trifluoromethylphenyfhydrazine in 20 mL of ethanol was refluxed for 6 hours
and then
stirred at room temperature for 48 hours. The reaction mixture was poured into
dilute
HCI solution and the product was extracted into EtOAc. The solution was dried
and
concentrated $nd the residues were chromatographed on silica gel with 10:1
hexanelEtOAc to give the title product which crystallized from pentane, 1.67 g
(52%),
m.p. 103 - 104°C.
Example 12
. 5-Amino-1-(2.6-dichloro-4-trifluoromethylphenyl)-4-(5-f3-hydroxypropyll-2-
methylbenzoyl)~-methyfthiopyrazole.
A solution of 0.530 g (1.0 mmol) of 5-amino-1-(2,6~iichloro-4-
trifluoromethylphenyl)-4-(5-[fi-methoxycarbonylethyl]-2-methylbenzoyl)-3-


CA 02272136 1999-06-O1
-29-
methytthiopyrazole in 10 mL of THF was cooled in an ice bath while 1.33 mL of
a 1.5
M solution of DIBAL in THF was added. The reaction mixture was warmed to room
temperature and then quenched with water. The product was extracted into
EtOAc,
dried and concentrated. The residues were chromatogn3phed on silica gel using
mixtures of hexane/EtOAc to elute the tifle product which was isolated as an
amorphous foam, 174 mg (3496). Anal. Calcd. for C22H2°O=N3SCI2F3: C,
50.97; H,
3.88; N, 8.10. Found, C, 51.10; H, 3.96; N, 7.60.
Example 13
I5 Amino-l-(2.6-dichloro-4-trifluoromethyfphenyl)-3-methylsuffonyl 1 H pvrazol-
4.-
y11-(2.5-dimethylphenyl)methanone
To a solution of 200 mg (0.42 mmol) of [5-amino-1-(2,6-dichloro-4-
trifluoromethylphenyi~3-methylsutfanyl-1 H-pyrazol-4-yl)-(2,5-
dimethyiphenyl)methanone
in 10 mL of THF was added 0.176 g (2.10 mmol) of anhydrous sodium bicarbonate
followed by a solution of 145 mg (0.42 mmol) of 3-chloroperoxyben=oic acid in
8 mL
of THF. After two hours at room temperature, 0.5 g of sodium bicarbonate and
an
additional 290 mg (0.84 mmol) of 3-chloroperoxybenzoic acid was added. The
reaction
mixture was heated briefly to 50°C, let cool and stirred overnight at
room temperature.
The reaction mixture was added to water and the product was extracted into
ethyl
acetate. The organic extracts were washed with dilute sodium bicarbonate
solution and
then dried and evaporated. The title compound was crystallized from ether to
give 150
mg (7096 yield) of colorless crystals, m.p. 193.5 - 194.5°C
Example 14
The following compounds in Tables 1 and 2 were prepared according to the
indicated Example.


Image


CA 02272136 1999-06-O1
-31-
a~



T T T~ 1- N N ~D T T T T


a'


z z


~ ~ ~ o i ~ N ~ ~i 'n


aaU c a c ~~ o
o o ~


T T T N T r N T T O O ~ T T
1 1 1 1 1 1 1 1 1 1


i~~ ~ ~ ~ M ~ N OMO~ ~ ~
p O tO


U r r r N r r N r .- C _
N i V M = ~ =


o


a a a a a a a a a a. ~~j
y~t


a E E E E E ~ ~ E E ~ _ E
a =N
'


_
C' ~ ~ ~ ~
O


~
~ Q U U ao U
ao


Z 2 Z Z I I I I I Z ~ Z Z



>.


a


0


a


OC o


U


U U ~ U U U U v U U U U


N Z N N N N N N N at N N N


to


U U U U U U U U~ U U ti


ca ca Z ca ca ca ca Z co ca ca ca ca



U U U U U U U U U
I l


~ r Z v v ~ ~ I ~t
r t


U U U U U U U U U U U


1 1 1 1 1 1 1 1 1 1 1


~ N
N N ~t N N N N N N N N


H


= I


U U U U U U = U U U U Z V


cn cn cn cn cn cn U cncn cn cn U cn


1'1


" " o 0 0 0
= = Z


_ _ U U U c _c c _c


_
E ~ Z o ~ o ~


c Z Z c c Z Z
a o o




CA 02272136 1999-06-O1
-32-
N m
N Q


01
E N r r N r r ~ r r r


~


d W


. Z


;a ... vi _c~ ~ o an N o v; V ~ ~j z o r c~
~ o o w o o


a~ a N r ~ ~ ao wn
0 o p U O O r r ~ ~ N CV p ~ N O ~ r r- r


R a O ~ (D CND~ N 000O O d O ~ '~t CO O O
= '


V ' ~ ' M ~ r r r N N ~ U O = ~ ~ r ~ r
~


~ E ~ ~ ~ c a a n' a a E a a a
~ j N ~ ~ =


r . . ~ .
a ~ E E E i ~


a~~ ~ ~ E E E a~ r E E E
In N tn t~


_ E=UUt~ EQUU~~ts


N


M
U



u. ~ U U U O U U U U U
, , , , , , , , ,


. ,
N N N M N N N N C9 C~ C~


U U U U U U U U U


ca I I co ca ca ~'r~ ~ ~ ~'r



U U u. U U U U U U U U
, , , , , , , ,


~ , ,
ca ~t ~t ~ ~ ca ca ca ca co


U U u. U U U U U
U U U
. , , , , . . ,


, .
N N N N N N N N N N N


n
e~ m n ,~ = n n n n en n


Z Z I I U Z Z Z Z I I


U U U U = U U U U U U


cn cn cn tn Z v7 cn cn cn cn cn



m
U


O


N IV N


f~ 1~1


Z Z U


U Z I U Z Z Z I Z I Z


Z Z Z Z Z Z Z Z Z Z Z




CA 02272136 1999-06-O1
-33-
N
d


_
N _ a
d


N T T T 1- 1- T T



co Z r


~.. N O . a0 vi N tfj
o Z


~o U N ca d. ~ ~ - U N r cN n
o T T O ~ O ~- r. T T
N V ~ Ch N 01
~


C O GO fn ~ ~ tf7N O 00
~ ~ fn
~ " L O ~ N
~
'~


U r r tn ' N T C~ ~t
N C~ _ ~ N -
O U ~


w ~ r T T r
~ a N = a a
~~Z~'n ~UZ


s ~ ' ~~ a a
'a a
~


a-- ~ ~ E ~ E E
c _- z ~r
~= v '=
'


01 ~ 7 a lC ~ ~


Z U U t~ E Q U U ac
~ r


I I I Z I Z U I



U U U U U U U U


O O N M N M N C~



U


tt''~ '~ _ = O =


v


U U U U U U U U


cc ca ca co ~t ~ ~t co


U U U U U U U U


N N N N N N N N


r
n ~n


n ~ ~ M
I I Z Z Z Z Z Z



N ~


Z



CC H U
..,


I Z


U Z Z I I Z Z Z


Z Z Z Z Z Z Z Z




CA 02272136 1999-06-O1
-34-
N
N


_
N


~ N r r r r


X
W


~Z Z


~N~ z N NV G~0~ ~
U N ~
~C~p
U


U _ _ _ .
~ (j
.


N _
~ ~
~


'p ~ ~ N ~O L
l0 B. -p N C'9CO r ~
_ ~ 'a
B. -p


U ~ r r r r (~ z
N
V
3


a ~ a a a a ~
Z ~U~v~=
EV~

~=


~ , . Q
n
Q


a .=co iri E E E E ~= o


a ~0 r ~t ~t' G. ca O ~ M
1~ ao c0 a0
o


~ Q U U r: E Q U U of ~.o
~ ~ i


Z Z Z V I Z



Z Z ~i


U U U U U U


C~ C~ N C'~C~


Z



ca = = t0 c0 c0



Q ~ ~i Z


U U U U U U


rt ~ ca


M
U U U U U U


N N N N N N


N
~ M


U


U U U U U


N


N



U I Z Z Z Z


Z Z Z Z U Z




CA 02272136 1999-06-O1
-35-
m


a
r r


r r r


a' u~



Z v


vi ~ n r~ ca vi '~~"~ -Z
UZ ~D N ~t 7
~? U


i V CV ap _
r r


a~U= ~~ ~ N ~ a~~= cc~


V i- V M ~ r r r ~ U


~~~~ n a a QU~~ta= a


r F U .~- - '
Q


-- _' Z c0 ~ M
T


~QUU~~~ EQUUaowao



Z I Z Z U


co



U


(j U U U U


cy c~ C~ M M


' Z I Z Z


U U U U U U


co ca ca ca ca ca


.r n n ~ n
U U


U U o~ U



M
U U


U U U U


(V N N N N N


n
I Z Z I Z Z



H N H H H


Z Z Z Z Z Z




CA 02272136 1999-06-O1
-36-
N _Q)
N
Q


_ r T-
O ~
V


O
'


a
w


U ~Z


c-Ia N V Z Z ui V ~ Z ui Z
U ~ ~ U
~ '


m o~ o
o U ' U U w ,
s .~ cn o is ~ ..- r~ ~ o ,~ bi .-
o


C ~ 00 Iw L _ ~ r L ~ O N
O
M


in d ~ p' _V Z ~ st p U ~ ~
O V Z ~


F _ ~ U Z= OZ fl.
_ Q
~ U ~ ~i


~
M U
n u.
H


O, N ~ ~ a l0 ~t in ~ i0 I ~ ~fJ
Q a6 p t O ~ tw c~ ~


Ea~a o Ea~ti~ ni ~ati~o o



n
CC = V ~ U I


vU



U U U U
O



Z


U, U a'D U


c ca
o



m U U


ca


Z _


U


N N N N


H


U Z


U U
U



n


Z Z Z Z




CA 02272136 1999-06-O1
-37-
N
N a
0 0 ~ n n ao ,-
°° = U " of Z
(/1 ~ r iA '~ Z Z N ~ O (p N C'7
ca U ~ ~ _ , w ~ o U V ~ U r co ~ ~ U is C) z
~ s U ~ N _~ t "' ~ ~ ~ t ~ o ~ ° ~ u7 ~-
L
a'~apn E ~''V CAN =N ~ C'7~D~ B'-p~Z CCV
~>,a Ea~~ H= E ~°cZ= oz ~.°,z~~ ~ ~aovii °z
E Qg N~~t QU=~u-T Qc~_~a QUr-N~'
c . = T . 6i
a Z .'~ ~ a. ~a _ao ~n ~ ~r c~ Q ~ _o ~ ~ a. ~a o ~r ~ ~r ,-
E = ~ .a' ~ v E Q U ~ of ~ of E = U V LL E Q U U r: ~
Z I Z U
U U U U
N N N
M
U U
co ca
U U U U
~t
U U U U
N N N N
V ~ V
U U U U
O O O O
n
U
Z Z Z Z


CA 02272136 1999-06-O1
-38-



~ _
~ ~ ~


O O r
lG



(~


ca j LL ~ fn ' ;~ N N C
~


~ ~ o o E u. o o V o
U ~ o E N ? ~ ~


O L ~. ' U o t :- '" -c O ti
~ E ~ ~
~


~~.. O n.o ~ ~ a- Z
~


U O O ~ L L 1~ O tn O T
' O O~ tn O
n C~ D7


fi E ~~.oor E ~~ z~~ E~cn ~r.
- Q~ a .~
E s ~


a~ N.ri=oo ~,~ Hoo v~ zoo


Q ~ ~ ~ N N a Ci ~ ~ a ~ ~ N ~
N ~ i~ ~


E=~UU~~ E=~U U~~ E=~ UU~'~


H Z U Z


DC V , U
7


v


" " I


U


N CV N


U V


ca
ca ca


V U U



V V


~t
N N


,
H U Z Z


U


~ U U


p UU



n n
Z


Z




CA 02272136 1999-06-O1
-39-
N _d
N _ a.
O O l0 M ~ c0
LIJ
M
U_ -Q Z
c0 ~ b ... ~ II v ~-. N C ih
~~,~ O ~ N = N ~ ~ ~ ~ O ~ w N ~ V Z
.cU~"»~r~o~= s ~ ~ N~ p.~Uei iri
~ a ~ ..: ~ ~"~ v a. ? ~ O o r .Q O ~ e?
v p.U vi=__ N~~ p ~co
Q~Zom:=n~: Q~N~°NO~ EV~N~°=
v ~ v ~ ~ ~ II ~ N ~ Z N
n' Z, C'~r~ !~ f~ (gyp ~ ~ a ~ ~ ~ N ~ N C.. !O tt7 r (NG. _tn
E=cviW v~~~ E=~UU..~ ~QUSjao~ao
Z
Z U
U '
M
Z
O
U U U
M N '
N
U U U
ca
V U
V V U
N N N
n
"' U
cV cV Z
U
!z
Z
Z


CA 02272136 1999-06-O1
-40-
N _d
N L1
U Q ~ ~O r r
co U NZ _z vi V ~UZ
c"'oU ~ ~_c~iZCjZ ~ ~V~U ~ ocne'~ c
t~UN~o s °cnr:o~ t~~~"~= w°n
c a.~0~ j~; a-a~= jr
>,n- ~ ~azo=t~_ ~ ~~N~°_ ~Uc°~cvi=
Q V_ _ ;_ ~ a V = r _, o a . Z ~ ~ o
Q 4f ~ ~ ~ ~ (NO. C. ~ N ~ N ~ 00 a ~ N U ~ p N
EQUWo»o~ EQUU~~~co ~QU..Zwts
N
M
S V U
U ,
' ~ Z
U H
v U
Z ii Z
U U U
N N N
CO ~O tD
v ,., w~
st
CC N N U
N
M
n
U
U
H N
Z


CA 02272136 1999-06-O1
-41-
N m
N a.



' .


a
ti



et ~' o vi ' U ~ Z


o ~' % ~
No s
~


. U c~ . c a Z
c a r ~
o o - 1~ O
O ~


C Q. .-: ~ ~ i V M
M a~ ~~~ - ~ t*
~ ' M O p U N N - Z
p ~ v~


N n' ~.~azo~'~ t== in== a a a a EUcov~u-=
Ea


U 3 C ~ ~ ~ Q l0 N ~ tG
Z O O ~ tD ~ CO
~


i ~ EQUUao~ao
=UU ~
~
=


t cat -
F cvc~
E


Z >.
O ,~ a


0


U I Z I Z o


I O N


U ~



U


U O U U U U


y N M M M M N


n
U U U U U Z U
U


co ca ca ca ca


U U U m U


'


~ ~
r


I


U U U U U U U


N N N N N


Z Z Z Z


U U U U


Z Z Z I I I Z


~ N O O O O



Z I Z Z Z Z Z


Z Z Z Z Z Z Z ,




CA 02272136 1999-06-O1
-42-
N d
N


T r r T


X



Z


N ca oo (~ Z Z


~ U ~ ~ U ago ~j r r
Z


O o O .~ N M tD ,= 1n O U7 r C ~ N
L


l0 ~ '~ Q ~ ~ T r O N r tn f~
~ Q 00
=
~


U V r3 C11r O ' M = ~ N
~ a a ~z a
U~


s E ~u-= ~ .
~U ~.
z


c ~ ~ a V = r C
v
Z O O


LL f0 CV tn
O r O ~ ~ ~ ~ O O '
CV r ~
~


C E U U U CD
r !1. r
E Q U U ati
~l7 I~


Z


O


n
I I Z Z I


U



d


o ~s _
U


l"1 O c ~ ~. s r-


U QU ~ ' U a~ ~ o'D U
a-


N , ~3a3~.~c c$ c%~
N



U U U U U


ca ca c~ ca cc


ti ti u:' ti O
n


Z


et ~ ~ ~t ~
Z


U U U U U


N N N N (V


N


Z ~ Z Z Z


U U U U U


N



N N N ~V
Z


Z Z Z Z Z




CA 02272136 1999-06-O1
-43-
n.
T T T T
T T T
N i~ Z tt7
c"'aU oo ~ ~ LNUZUZ ~ ~N~UZ
T N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ T T T T T
s~pOo~~cv a p ccv ~ u' ~ rw.
~ N ~ V d' T ~ '~ ~ L ~ ~ ~ ~ T T T T T
o _ Z = a ~ Z tL T
~ a ~ V r~ ~ = u. = Q U N °T° = Q. a a a
~ ~ o ~ ° o a°°o ao ~ = 00 C N N ~ ~ E ~ E
Q l0 T ~ I~ ~ tn
Ear i~a ~a Ea~V°~°
Z Z Z I Z Z I V U
N ~'I
j,
U U U c
a~
Z Z Z Z Z
O O O 0 ~ v U U
pj M Ch M ('~ N Z N N
,_n ~ ~ M n
U U U U U U U U a0
ca co co ca ca co ~ v v
" " u= Z
U ao U c~ U U U U U
~t v ~ ~ ~ ~'r ca c~ c~
= Z Z
U U U U U U U U U
N N N N N N N N N
N
U U U U U U U
cn cn cn cn cn cn cn U U
Z Z Z I I Z Z Z I
Z Z Z Z Z Z Z Z Z


CA 02272136 1999-06-O1
-44-
N C)
N


T IC~ T T T ~ T 1~



M N 00 I I In
LI O
O


~ tn ~ ~ M ~ I~
o U o ~~ '
~ '


. ' O O
O O
~ O


_ tn N ~ ~ V ~
~ O ~
t


C7 ~ D ~ U Z V D7 r f~. ~ ~ l0 M ~_ O)
Z ~ 1D r


U ~ v U ~ U ~n
~ '~ O CO T a O) Q O) O
~ 'C


a E = o ~ ~ tn ~ ~ N ~ ~ U-
~ ~ M


U ~''~ ~ ~ o ~ cn ~ r~ ~n ~
i ~ ~


U U i i o
t ~ C


t =~i~ =~t =~iti



Z I V I Z = ~


c



H


V Z ~ ~, Z I


Z U U a a U U U


, , , , , , ,
N N l'~N N N N


W_ ,~ e~ n m n
U U U U U


, U , , , U U
, , ,


v


v


U U U U U U U U
, , , , , ,


, ,.
ca ca co ca co co ca ca


U U U U U U U U
, , , , , ,


, ,
N N N N N N N N


n I
U Z I


I I Z I Z


U U O U U U U U



Z


n
U
v
n


U I


Z _ Z Z I U Z Z
Z


Z Z Z Z Z Z Z Z




CA 02272136 1999-06-O1
-45-
m


r Ln III lf~ tl7 r


'


a
w


of
N


c~,a ~ N ~ o
U ~


p N (~D r t~ ~ tI~
' ' "0 'fl ~ r 'Q O
r r


C p r fl O ~ ~ U U U U
c0 ._ U ~ ~ r ~ ch ~ c
c~ ~


,, ~ ~ 0 O
Q ~ U ~ ~ U yn U yn
~ r
U


n U ~ ~ ~ ~ N c ~ r N O
' ~ U ~ ~ ~ v
fn fn ~ M ~ ~
'a ~ N


r a r r ~ C
C C O ~
~


~ tn ~ M ~ ~ ~ 0~ C ~ cD O O
O O ~ O ~ O LL
~ u =
= l


= W = ~ ~ ~ = ll7 LL . L
LL LL v IL _ t17 ~
-


Z
a n'_ a a. a n- V



>.
a.



z Z Z Z z Z


U U U U U U c


N N N N N N N


' ~ " LL LL _ LL lL
U U U U U U


U



<_


U U U U U


ca c~ ca ca ca ca ca


U U U U U U U


N N N N N N N


n
eo n M ~ ~ n


U
U U ~ a


cn U ~ c c
n n


Z ~ Z Z
"


N n U
H U v ...
U


~ Z ~ _
Z = c Z


H ~ U ~ U V
I Z


Z Z Z Z~ Z Z




CA 02272136 1999-06-O1
-46-
a~


a
V


r LC7
O ~ r r r r r r r r r r
0


W


C


r ~ ~ C'~7'Ct O r
~ ~ ca r. r ~ M r. .. a~ ~ N c~


c (~O ~ p N N N ~ ~ ~ .~ r N N
a U ~ ~ N 0


c O '~ 'Q O N N 1 OD i O r O 0 N
~ ' O U r In C9 t~ tn O r
U ' t~
r
r


0 U to l0 ~ N N N r ~ ~ r r N N
V ZC Q 1~I7


U yn U N U ~ a a. a. a r. a. a. a a
u~ ~ ~
~


t lno~ (OTC (~O ~r~N ~ E E


~ ~
~


~ r In ~ ~ ~ CO
~ ~ O



a
d '


n o a' V U U U = U ao a m a'o
o


cc a ~j ~ ca ca ca ~i v ~i uiv


c



I z z z


a


U U U U U U O O O O O m
, , , , , , , , ,


N , , N N N N N N N N N
N N


U U


U U U U U U U U U U
, , , , , , , , ,


, , , ca ca ca ca ca ca ca coca
ca


_a ~ ~ M
U U


U U U U m U U m U U
, , , , , , , ,


, , , ~ ~ ~r st ~t
ca ca ~


Z I


U U U U U U U U U U U U


N N N N N N N N N N N N


n
Z M n n ,~ n ,~ ,~ w, ~ n e~
Z Z Z I Z Z Z Z I Z I


U U U U U U U U U U U U



I
N


~ U


~ t tV N N fV N N


H V n N H V I Z Z Z Z Z
I Z Z Z I


Z Z Z Z Z Z Z Z Z Z Z Z




CA 02272136 1999-06-O1
-47-
N
d


_
N
v.


r' T T T T T r T !- T T


X


N


_ "'
~ ~ ~ b _
~ ~: N
(O _


/~ CO ~ lI71~ 00 O ~ _
n 1~
O1


_ _ _ _ _ ~ T
N ~ n 0 D 1 O O M M O ~ M N
~ ~


= I~ !~ t 0 ~ t ' ~ ~ _
lLf O ' 7 00 O ~ v v
1~


.~ T T T r ~ T r O ~
T 1- r O r U
"' ~ N ~j tD ~ I~
N N


t - a a. d a d a a a a V
~_ ~"~rN~'y.'~
==~N~


F E E ~ F F F E ~ _M
~- z
N
~


a ~ roc~ ~~ c
r~a
a a
'


= a~ co co
' o


OrN ~.n~~7'7


N N N N N
N L L L


, 1 1 Z
Z Z Z



r
I


L L ~ _ = ti Z I U


m m m U U U U U U U O


N N N N N N N N N N N


U U U U U


U U U U U U


co ca co co ca co ca ca co caca



U U


OD a0 U U U o0 U U U
, , , ,


, , , , , , ,
~t v ~ ~ c ~r v ~ v v ~t


I Z Z Z I


U U U U U U U U U U U
, , , , ,


, , , , , ,
N N N N N N N N N N N


N
~ n c~ n ~ ~ n n


_ = Z = _ _ _ = Z =


U U U U U U U U U U U



N N N N N N N N N N N


Z




CA 02272136 1999-06-O1
-48-
TABLE 2
R3
0=C SCH3
N
H2N N~
Ra
Phys. Data Process of


R3 R4 (m.p. in C) Example


CZHSCHC4H9 2,6-CIZ-4-CF3Ph HRMS Calcd. 1


467.0809.


Found


467.0913.


C3H,CH=CH-CZHS 2,6-C1z-4-CF,Ph FAB Mass 1


Spectrum:
466


2-methylcyclopentyl2,4,6-CI3Ph HRMS Calcd. 1


417.0236.


Found


417.0328.


2-OCZHS-1-naphthyi2,6-CI2-4-CF3Ph m.p.149-151 1


2-OCZHS-1-naphthyl2,4,6-CI3Ph m.p. 125-128 1


3_CF3-Ph 1,3-(CH3)2-4-NOZCalcd. for


PYr~ol-5-yl C"H, 5O3NBSF3:


C, 46.36;
H,


3.43; N, 19.08.


Found: C,


46.51; H,
3.37;


N, 18.10.





CA 02272136 1999-06-O1
-49-
Example 15 .
A. 3-Trifluoromethylphenylthioacetonitrile.
To sodium (0.62 g, 27.0 mmol) dissolved in 40 mL of ethanol was added 4.79
g (26.9 mmol) of 3-trifluoromethytthiophenol and 2.04 g (27.0 mmol) of
chloroacetonitrile. The reaction mixture was heated at reflux for 1 hour and
then
stirred overnight at room temperature. To the cooled reaction mixture was
added one
volume of ether and the precipitated solids were removed by filtration. The
filtrate was
evaporated on the rotary evaporator to give the product as an oil in
essentially
quantitative yield. This material was used in the following reaction without
further
purification.
8. 3-Trifluoromethylphenylcyanomethylsulfoxide.
A solution of 3.00 g (13.8 mmol) of 3-trifluoromethylphenylthioacetonitrile in
130
mL of methylene chloride was cooled to 5°C under dry Nz and treated
with 4.89 g
(28.35 mmol) of m-chloroperbenzoic acid. The reaction mixture was stirred for
48
hours at room temperature and then cooled in ice, after which the insolubles
were
removed by filtration. The filtrate was washed with 10~°sodium sulfate
solution until
all traces of peroxides had been removed and then dried over magnesium sulfate
and
evaporated to a pale yellow oil which was used in the subsequent reaction
without
further purification.
C. 3,3-Bis-methytthio-2-(3-trifluoromethylphenylsulfonyl)acrylonitrile.
A solution of 13.82 mmol (crude product) of 3-
trifluoromethylphenyicyanomethylsulfoxide in 30 mL of dry dimethylsuifoxide
and 1.25
mL (1.58 g, 20.7 mmol) of CS2 was cooled to about 15 ° C in an ice bath
under dry
nitrogen. Then 0.99 g (41.5 mmol) of oil-free sodium hydride was added
portionwise
below 20°C and the deep red solution was let stir at room temperature
for 75
minutes. The reaction mixture was cooled to 15 ° C, quenched with 2.58
mL (5.89 g,
41.5 mmol) of methyl iodide and let stir overnight at room temperature. The
reaction
mixture was poured into ice/water and let granulate for 3.5 hours. The product
was
filtered and air dried to give 3.51 g (72%) of the product. The analytical
sample was
crystallized from EtOH/HzO, m.p. 109-110°C.


CA 02272136 1999-06-O1
-50-
D. 5-Amino-1-(2 6-dichloro-4-trifluoromethylphenyll 4 l3
trifluoromethvlbenzenesulfonyl)-3-methylthiopyrazole.
A suspension of 0.50 g (1.42 mmol) of 3,3-bis-methylthio-2-(3-
triftuoromethylphenylsulfonyl)acrylonitrile and 0.35 g (1.42 mmol) of 2,6-
dichloro-4-
trifluoromethylphenyihydrazine in 10 mL of ethanol was heated at reflux for
2.5 hours,
solution occurring as the reaction mixture was warmed. The mixture was stirred
overnight at room temperature and was then poured into cold water. The product
was extracted into ethyl acetate and the extracts were dried with magnesium
sulfate
and evaporated. The residues were crystallized from ether, and the product was
filtered off and air dried to give 314 mg (4096) of the desired product, m.p.
201 -
203°C. Anal. Calcd. for C,eH"OZN,SZCIZFe: C, 39.28; H, 2.02; N, 7.64.
Found: C,
39.35; H, 2.19; N, 7.48.
E. 5-Dimethylamino-1-(2 6-dichloro-4-trifluoromethylphenvl) 4
(benzenesulfonyl)-3-methylthiopvrazole.
A solution of 0.241 g (0.5 mmol) of 5-amino-1-(2,6-dichloro-4-
trifiuoromethylphenyl)-4-(benzenesutfonyl)-3-methylthiopyrazole in 5 mL of dry
dimethylsulfoxide was treated with 36 mg (1.5 mmol) of oil-free sodium hydride
under
dry nitrogen in a flame-dried flask at room temperature. After 30 minutes, a
clear, pate
yellow solution had formed. This solution was treated with 0.5 mL (8.0 mmol)
of
methyl iodide and stirred for 1 hour. Then the reaction mixture was poured
into water
and extracted twice with ethyl acetate. The combined extracts were dried with
brine
and with magnesium sulfate and evaporated. The residues crystallized from
ether to
give the desired product in 819'a yield, m.p. 163 - 164 ° C.
Example 16
The following compounds were prepared in accordance with Example 15.


CA 02272136 1999-06-O1
-51-
SC2 SCH3
I
/N
R N
m
R1 R15
y t

R" R,3,R",R,S R, M.P. (C) or
Analysis


H 2,4,6-trichloroNHz 161-162


H 2,4,6-trichloroN(CH3)2 200-202


2-(i-Propyl)2,4,6-trichloroNH2 180-182


2-OCH3 2,4,6-trichloroNHz 212-215


2-Ci 2,4,6-trichloroNHz Anal. Calcd. for
C,BH"OZN3SZCI4: C, 39.60;
H, 2.39; N, 8.33. Found:
C,39.76; H, 229; N, 8.69


H 2,6-C!2-4-CF3NHZ 209.5-210.5


H 2,6-CI~-4-CF3N(CH3)Z 163-164


3-CF3 2,6-CIZ-4-CF3NH2 201-203


3-CF3 2,6-CIZ-4-CF3N(CH3)z 137-138


Example 17
4-(2-Chlorophenyll-1-(2.6-dichloro-4-trifluoromethvlphenvll-3-
methylthiopyrazolo f3.4-dlpyrimidine.
A suspension of 669 mg (1.39 mmol) of 5-amino-1-(2,6-dichloro-4
trifluoromethylphenyl)-4-(2-chlorobenzoyl)-3-methylthiopyrazole in 5 mL of
formamide
was heated at 150°C overnight. A pale yellow solid precipitated upon
cooling of the


CA 02272136 1999-06-O1
-52-
reaction mixture. A total of 50 mL of water was added to the stirred
suspension to
complete the precipitation of the product which was filtered off and washed
with water.
An inseparable trace of starting material was observed in the product by thin
layer
chromatography (TLC) and so the above procedure was repeated on the mixture
giving a brown solid containing no trace of starting material. Trituration of
this solid
with methylene chloride gave a pale yellow solution which was concentrated to
give
the desired product as a white crystalline solid, m.p. 156-158°C.
Example 18
The following compounds were prepared in accordance with Example 17.
R3
., ~SCH3
R
R13
R3 R9 R,3 m.p.(C) or HRMS


2-CI-Ph H CI 193-195


3-CI-Ph H CI 171-173


2-C(-Ph H CF3 156-158


2-CI-Ph OH CI 313-316


2-CI-Ph CI CI 193-195


2-CI-Ph 4-ethoxycarbonyl-CI 222-225
piperazinyl


1-naphthyl H CF3 171-173


2-CI-Ph CH3 CI 210-212


2-CH3-5-iPrPhCH3 CI 141-142




CA 02272136 1999-06-O1
-53-
R3 Rs R,3 m.p.(C) or HEMS


2,6-(CH,)~-PhCH3 CI HRMS Calcd. 462.0239.


Found, 462.0369.


2-(OCZH5)-Ph CH, CI 189.192


2-(OCZH5)-1- CH3 CI HRMS: Calcd.: 528.0345


naphthyl Found: 528.0226



2-OCH3-Ph CH, CI 214-216


2-CZHS-Ph CH3 CI HRMS: Calcd. 462.0239


Found: 462.0219


Ph CH3 CF3 114-116


2,5-(CH3)~-PhCH3 CF3 HRMS: Calcd. 497.0579


Found: 497.0602


2-CF3-Ph CH3 CI HRMS: Calcd. 501.9800


Found: 501.9778



Representative Drawing
A single figure which represents the drawing illustrating the invention.
Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 2004-12-07
(22) Filed 1993-11-03
(41) Open to Public Inspection 1994-06-23
Examination Requested 1999-06-01
(45) Issued 2004-12-07
Deemed Expired 2006-11-03

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Request for Examination $400.00 1999-06-01
Registration of a document - section 124 $50.00 1999-06-01
Application Fee $300.00 1999-06-01
Maintenance Fee - Application - New Act 2 1995-11-03 $100.00 1999-06-01
Maintenance Fee - Application - New Act 3 1996-11-04 $100.00 1999-06-01
Maintenance Fee - Application - New Act 4 1997-11-03 $100.00 1999-06-01
Maintenance Fee - Application - New Act 5 1998-11-03 $150.00 1999-06-01
Maintenance Fee - Application - New Act 6 1999-11-03 $150.00 1999-07-29
Maintenance Fee - Application - New Act 7 2000-11-03 $150.00 2000-07-21
Maintenance Fee - Application - New Act 8 2001-11-05 $150.00 2001-07-18
Maintenance Fee - Application - New Act 9 2002-11-04 $150.00 2002-09-17
Maintenance Fee - Application - New Act 10 2003-11-03 $200.00 2003-09-17
Final Fee $300.00 2004-08-30
Maintenance Fee - Application - New Act 11 2004-11-03 $250.00 2004-09-16
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
PFIZER LIMITED
Past Owners on Record
FARACI, WILLIAM S.
WELCH, WILLARD M., JR.
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Representative Drawing 1999-08-31 1 1
Description 2003-02-19 57 1,941
Claims 2003-02-19 4 126
Description 1999-06-01 56 1,932
Cover Page 1999-08-31 1 27
Claims 1999-10-12 4 139
Abstract 1999-06-01 1 15
Claims 1999-06-01 4 137
Claims 2004-04-20 3 66
Description 2004-04-20 57 1,942
Cover Page 2004-11-02 1 31
Assignment 1999-06-01 2 93
Prosecution-Amendment 1999-07-14 2 2
Prosecution-Amendment 1999-10-12 2 67
Correspondence 1999-11-04 1 1
Correspondence 1999-06-17 1 40
Prosecution-Amendment 2002-08-19 3 87
Prosecution-Amendment 2003-02-19 9 283
Prosecution-Amendment 2003-10-20 2 64
Correspondence 2004-08-30 1 29
Prosecution-Amendment 2004-04-20 7 189